BCA
ELGX

Berman Capital Advisors’s Endologix Inc ELGX Stock Holding History

Berman Capital Advisors’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-279
Closed -$2K – 1683
2019
Q2 		$2K Buy
+279
New +$1.9K ﹤0.01% 1279

Other funds holding ELGX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Berman Capital Advisors's ELGX Position: Q3 2019 in Review

Berman Capital Advisors sold out of Endologix Inc (ELGX) in Q3 2019, closing a stake of 279 shares — an estimated $2K sold.

Berman Capital Advisors first reported a position in ELGX in Q2 2019 and held it in 1 quarter. The position peaked at $2K in Q2 2019. 63 funds tracked by Wall St. Rank hold ELGX as of Q3 2019.

  • Berman Capital Advisors reported no remaining Endologix Inc position as of Q3 2019 after selling out during the quarter.
  • Berman Capital Advisors sold 279 Endologix Inc shares in Q3 2019, an estimated $2K.
  • Berman Capital Advisors first reported a position in Endologix Inc in Q2 2019 and held it in 1 quarter.
  • Berman Capital Advisors's Endologix Inc position peaked at $2K in Q2 2019.
  • 63 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2019.

Based on Berman Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.